- Home
- KRMD vs MIRM Comparison
KRMD vs MIRM Comparison
Compare KRMD & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRMD
- MIRM
- Stock Information
- Founded
- KRMD 1980
- MIRM 2018
- Country
- KRMD United States
- MIRM United States
- Employees
- KRMD N/A
- MIRM N/A
- Industry
- KRMD Medical/Dental Instruments
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- KRMD Health Care
- MIRM Health Care
- Exchange
- KRMD Nasdaq
- MIRM Nasdaq
- Market Cap
- KRMD 103.4M
- MIRM 1.9B
- IPO Year
- KRMD N/A
- MIRM 2019
- Fundamental
- Price
- KRMD $2.47
- MIRM $40.80
- Analyst Decision
- KRMD Strong Buy
- MIRM Strong Buy
- Analyst Count
- KRMD 4
- MIRM 11
- Target Price
- KRMD $4.88
- MIRM $58.55
- AVG Volume (30 Days)
- KRMD 145.7K
- MIRM 438.4K
- Earning Date
- KRMD 05-07-2025
- MIRM 05-07-2025
- Dividend Yield
- KRMD N/A
- MIRM N/A
- EPS Growth
- KRMD N/A
- MIRM N/A
- EPS
- KRMD N/A
- MIRM N/A
- Revenue
- KRMD $33,646,463.00
- MIRM $336,888,000.00
- Revenue This Year
- KRMD $16.50
- MIRM $29.51
- Revenue Next Year
- KRMD $15.47
- MIRM $20.27
- P/E Ratio
- KRMD N/A
- MIRM N/A
- Revenue Growth
- KRMD 17.98
- MIRM 80.76
- 52 Week Low
- KRMD $1.86
- MIRM $23.83
- 52 Week High
- KRMD $5.05
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- KRMD 46.18
- MIRM 45.27
- Support Level
- KRMD $2.36
- MIRM $38.22
- Resistance Level
- KRMD $2.52
- MIRM $39.87
- Average True Range (ATR)
- KRMD 0.22
- MIRM 2.27
- MACD
- KRMD 0.06
- MIRM 0.23
- Stochastic Oscillator
- KRMD 91.04
- MIRM 61.83
About KRMD KORU Medical Systems Inc. (DE)
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.